Spark Biomedical CEO Discusses Neurostimulation Breakthroughs in Women's Health and Opioid Treatment

Daniel Powell, President and CEO of Spark Biomedical, brings over 25 years of medical device expertise to the company's innovative work in wearable neurostimulation. Spark Biomedical developed the FDA-cleared Sparrow Ascent, a novel wearable neurostimulation solution designed to address opioid withdrawal and addiction in adults. Under Powell's leadership, the company is also advancing a solution for Neonatal Opioid Withdrawal Syndrome, targeting the most vulnerable victims of the opioid epidemic.

The company recently received significant funding from Wellcome Leap, a historic and prestigious organization, which Powell describes as a game-changer for Spark. This funding will enable the company to conduct an FDA-style clinical study, the final step toward obtaining FDA clearance and CE mark approval to bring their women's wellness product, OhmBody, to market globally. Spark stands out as the only non-research institution among the awardees, highlighting the clinical validity of their work.

OhmBody, Spark's women's wellness division, emerged from research on neurostimulation for improving hemostasis—using the nervous system to enhance blood clotting. Initial clinical trials focused on women with heavy menstrual bleeding yielded remarkable results: a 55% reduction in blood loss and a 20% shorter cycle time. Participants also reported significant reductions in cramping and improvements in energy and mood, revealing the product's potential as a comprehensive menstruation solution rather than merely a blood loss reduction tool.

Looking ahead, Spark aims to expand OhmBody's offerings to address other women's health conditions such as endometriosis, PCOS, and menopause. The company also plans to develop hemostasis solutions for non-compressible hemorrhages, including GI bleeds, and applications for surgical and traumatic blood loss. Powell emphasizes that women's health has been severely neglected, and Spark's mission is to leverage wearable neurostimulation to tackle these unmet needs effectively.

Powell acknowledges challenges in the medtech space, including changing behaviors where people traditionally opt for pills despite side effects, and navigating complex regulatory and reimbursement landscapes with bodies like the FDA and CMS. He stresses the importance of scientific rigor in building partnerships, noting that Spark's success with researchers, healthcare providers, and funders stems from a commitment to doing the science right. This approach has positioned Spark to make a profound impact on both opioid addiction treatment and women's health innovation.